Explore more publications!

Louisiana Industry Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Industry Journal.

Press releases published on October 8, 2025

Elevating Every Arrival: The Guide to Choosing a Limousine in New Orleans
From Cypress Trees to Streetcars: How Louisiana’s Dual Tours Capture Its Dual Spirit
Setting the Mood: How Audio Systems Transform Home Gatherings and Events
The Power of Connection: How Emotional Advertising Drives Engagement Across Every Marketing Channel
 Integrating SEO Advertising and Marketing to Strengthen Digital Authority
Beyond the Shine: How to Identify Jewelry That Truly Holds Its Value
Disability Insurance: An Overlooked Safety Net for Young Adults
Analysts Predict 2026 Will Be Breakout Year for Pre-Owned RV Industry
Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo
ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…
Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif
Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO
Nilo Therapeutics 啟動 1.01 億美元 A 輪融資,推進針對免疫疾病神經迴路的新型藥物研發,並任命 Kim Seth 為行政總裁
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…
Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…
Nilo Therapeutics 启动 1.01 亿美元 A 轮融资,以推进靶向免疫疾病神经回路的新型药物研发,并任命 Kim Seth 为首席执行官
Avidian Gold Corp. Files Early Warning Report in Respect of High Tide Resources Corp.
FRE Shatters Nicotine Pouch Norms with First High-Strength Watermelon, Answering Overlooked Consumer Demand
Osisko Développement annonce un placement par voie de prise ferme au titre de la Dispense pour financement de l’émetteur coté de 30 millions de dollars canadiens d’actions accréditives nationales et d’actions accréditives de la…
B2Gold Third Quarter 2025 Financial Results – Conference Call Details

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions